ORGANIC
LETTERS
2011
Vol. 13, No. 15
3988–3991
Total Syntheses of (ꢀ)
Epilupinine and (ꢀ)-Tashiromine
Using Imino-Aldol Reactions
Amanda C. Cutter,† Iain R. Miller,† John F. Keily,‡
Richard K. Bellingham,§ Mark E. Light,† and Richard C. D. Brown*,†
The School of Chemistry, The University of Southampton, Highfield, Southampton
SO17 1BJ, U.K., Prosidion Ltd., Transport Way, Cowley, Oxford OX4 6LT, U.K., and
Chemical Development, GlaxoSmithKline Pharmaceuticals, The Old Powder Mills,
Leigh, Tonbridge, Kent TN11 9AN, U.K.
Received June 3, 2011
ABSTRACT
Short routes to enantiomerically pure indolizidine and quinolizidine alkaloids have been developed using imino-aldol reactions of enolates
derived from phenyl 5-chlorovalerate. High levels of syn selectivity (dr ∼13ꢀ16:1) were obtained using lithium enolates of phenyl esters in
combination with tert-butylsulfinyl imines. The imino-aldol adducts were deprotected and cyclized to afford (ꢀ)-epilupinine ((ꢀ)-2) and (ꢀ)-
tashiromine ((ꢀ)-1) in two further steps.
(þ)-Tashiromine ((þ)-1) and (þ)-epilupinine ((þ)-2) are
5-hydroxymethylated indolizidine and quinolizidine alka-
loids respectively,1 possessing common relative and abso-
lute stereochemistry at C5 and C6 of their bicyclic ring
systems. (þ)-Tashiromine was first isolated in 1990 from
Maackia Tashoroi,2 whereas epilupinine has been known
for considerably longer. (þ)-Epilupinine was reported as a
product of the epimerzation of (þ)-lupinine,3 but it exists
naturally as a secondary metabolite in various members of
the lupin family.4 (þ)-Epilupinine has been shown to
exhibit in vitro inhibitory activity against Leukaemia
P-388 (LD50 = 28 μg/mL) and lymphocytic Leukaemia
L1210 (LD50 = 28 μg/mL) cells.5 Both natural products
(5) Hua, D. H.; Miao, S. W.; Bravo, A. A.; Takemoto, D. J. Synthesis
1991, 970–974.
† The University of Southampton.
(6) For selected asymmetric total syntheses of epilupinine: (a) Nagao,
Y.; Dai, W.-M.; Ochiai, M.; Tsukagoshi, S.; Fugita, E. J. Org. Chem.
1990, 55, 1148–1156. (b) West, F. G.; Naidu, B. N. J. Am. Chem. Soc.
1994, 116, 8420–8421. (c) Naidu, B. N.; West, F. G. Tetrahedron 1997,
53, 16565–16574. (d) Mangeney, P.; Hamon, L.; Rassou, S.; Urbain, N.;
Alexakis, A. Tetrahedron 1998, 54, 10349–10362. (e) Ma, S.; Ni, B.
Chem.;Eur. J. 2004, 10, 3286–3300. (f) Ahari, M.; Perez, A.; Menant,
C.; Vasse, J.-L.; Szymoniak, J. Org. Lett. 2008, 10, 2473–2376. (g) Su,
D. Y.; Wang, X. Y.; Shao, C. W.; Xu, J. M.; Zhu, R.; Hu, Y. F. J. Org.
Chem. 2011, 76, 188–194.
‡ Prosidion Ltd.
§ GlaxoSmithKline Pharmaceuticals.
(1) For the most recent in a series of reviews dealing with indolizidine,
and quinolizidine alkaloids: (a) Michael, J. P. Nat. Prod. Rep. 2008, 25,
139–165. For lupin alkaloids: (b) Ohmiya, S.; Saito, K.; Murakoshi, I.
In The Alkaloids: Chemistry and Pharmacology; Geoffrey, A. C., Ed.;
Academic Press: 1995; pp 1ꢀ114. (c) Saito, K.; Murakoshi, I. In Studies in
Natural Products Chemistry, Vol. 15: Structure and Chemistry, Part C;
Atta-ur-Rahman, Ed.; Elsevier Science B. V.: Amsterdam, Netherlands,
1995; pp 519ꢀ549.
(7) For selected asymmetric total syntheses of tashiromine, see ref 6a
and: (a) Gage, J. L.; Branchaud, B. P. Tetrahedron Lett. 1997, 38, 7007–
7010. (b) David, O.; Blot, J.; Bellec, C.; Fargeau-Bellassoued, M.-C.;
(2) Ohmiya, S.; Kubo, H.; Otomasu, H.; Saito, K.; Murakoshi, I.
Heterocycles 1990, 30, 537–542.
(3) For the epimerization of lupinine to epilupinine: (a) Winterfeld,
K.; Holschneider, F. W. Chem. Ber. 1931, 64, 137–150. (b) Sparatore, A.;
Tasso, B.; Boido, V.; Sparatore, F. Helv. Chim. Acta 2005, 88, 245–251.
(4) (a) White, E. P. N. Z. J . Sci. Technol., Sect. B 1951, 33, 50–54. (b)
Beck, A. B.; Goldspink, B. H.; Knox, J. R. J. Nat. Prod. 1979, 42, 385–
398.
ꢀ ꢀ
Haviari, G.; Celerier, J.-P.; Lhommet, G.; Gramain, J.-C.; Gardette, D.
J. Org. Chem. 1999, 64, 3122–3131. (c) Banwell, M.; Beck, D. A. S.;
Smith, J. A. Org. Biomol. Chem. 2004, 2, 157–159. (d) Dieter, R. K.;
Chen, N.; Watson, R. T. Tetrahedron 2005, 61, 3221–3230. (e) Conrad,
J. C.; Kong, J.; Laforteza, B. N.; MacMillan, D. W. C. J. Am. Chem. Soc.
2009, 131, 11640–11641.
r
10.1021/ol2015048
Published on Web 07/11/2011
2011 American Chemical Society